Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "User talk:Tindle Lisa/My sandbox Support page v2"

From Bioblast
(Created page with " {{Template:OROBOROS header page name}} <big><big>'''"A reprogramming-based strategy for drug repositioning in patients with mitochondrial DNA-associated Leigh syndrome (MILS...")
 
Line 17: Line 17:


===Aims===
===Aims===
 
The project aims to use iPSCs and reprogramming-drived drug discovery for finding therapies against MILS. A personalized medicine approach will be applied and compound screenings on patient-derived neural cells will be carried out. Brain organoids and multi-omics analysis will be used for validations.
1. Establishment of PDE5 inhibitors as reference drugs for MILS  
1. Establishment of PDE5 inhibitors as reference drugs for MILS  
2. Large-scale screen of marketed compounds in MILS neural cells
2. Large-scale screen of marketed compounds in MILS neural cells
3. Validations of hit compounds in MILS neural cells
3. Validations of hit compounds in MILS neural cells
4. Validations of hit compounds in neural cells carrying LS-associated Complex I mutations
4. Validations of hit compounds in neural cells carrying LS-associated Complex I mutations
5. Computational analysis of MILS neural cells and treatments


5. Computational analysis of MILS neural cells and treatments
===Objectives===
===Objectives===
:::: '''WP1''' - Name of person and/or instution responsible for this workpackage
:::: '''WP1''' - Name of person and/or instution responsible for this workpackage
::::*  Bullet points of WP objectives
::::*  Bullet points of WP objectives
Line 102: Line 99:
   
   
== Support ==
== Support ==
This project has received funding from the European Joint Programme on Rare Diseases (EJP RD).
Funded projects:  https://www.ejprarediseases.org/index.php/funded-projects-2020/

Revision as of 11:13, 21 December 2020


                



User talk:Tindle Lisa/My sandbox Support page v2

"A reprogramming-based strategy for drug repositioning in patients with mitochondrial DNA-associated Leigh syndrome (MILS)"



"Project Name": "Funding Scheme"

  • EJP RD JTC 2020: "PRE-CLINICAL RESEARCH TO DEVELOP EFFECTIVE THERAPIES FOR RARE DISEASES” - Project EJPRD20-010
  • Duration: 36 months
  • Start:
  • Web:

About CureMILS

Led by Prof. Dr. Alessandro Prigione of the Heinrich Heine University, the CureMILS project aims to employ a novel approach to enable drug discovery of MILS.

Aims

The project aims to use iPSCs and reprogramming-drived drug discovery for finding therapies against MILS. A personalized medicine approach will be applied and compound screenings on patient-derived neural cells will be carried out. Brain organoids and multi-omics analysis will be used for validations. 1. Establishment of PDE5 inhibitors as reference drugs for MILS 2. Large-scale screen of marketed compounds in MILS neural cells 3. Validations of hit compounds in MILS neural cells 4. Validations of hit compounds in neural cells carrying LS-associated Complex I mutations 5. Computational analysis of MILS neural cells and treatments

Objectives

WP1 - Name of person and/or instution responsible for this workpackage
  • Bullet points of WP objectives
WP2 - Name of person and/or instution responsible for this workpackage
  • Bullet points of WP objectives


Coordinator


Network

Participants/Beneficiaries

  • Fraunhofer IME, Department ScreeningPort,
  • Institute for Molecular Biology, Innsbruck University
  • Radboud University Medical Center, Biochemistry
  • University of Helsinki, Research Program of Stem Cells and Metabolism
  • Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, Department of Molecular Biology
  • Verona University, Department of Diagnostics and Public Health
  • Luxembourg Centre for Systems Biomedicine (LCSB) University of Luxembourg
  • International Mito Patients (IMP)

Collaborators

  • Charité University, Clinic for Pediatrics and Neurology
  • Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich Heine University
  • Oroboros Instruments GmbH
  • Foundation IRCCS Neurological Institute C. Besta, Unit of Molecular Neurogenetics
  • University of Milan, Department of Medical Biotechnology and Translational Medicine
  • Max Planck Institute for Molecular Genetics
  • Deutsches MITONET e.V., Friedrich-Baur-Institut


Oroboros project involvement

Oroboros is a collaborator on the project providing infrastructure and expertise required to conduct respirometric measurements for the project.


CureMILS events

CureMILS publications

CureMILS dissemination

Links

Social Media

Research Networks

References

Additional information

Support

This project has received funding from the European Joint Programme on Rare Diseases (EJP RD).

Funded projects: https://www.ejprarediseases.org/index.php/funded-projects-2020/